Skip to main content

Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Lupin Receives approval from USFDA for Dolutegravir and Rilpivirine Tablets

    Global pharma major Lupin Limited announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Dolutegravir and Rilpivirine Tablets, 50 mg/25 mg, to market a generic equivalent of Juluca® Tablets, 50 mg/25 mg of ViiV Healthcare Company.

  • Dr. Reddys Lab acquired trademark rights of product from Pfizer

    Dr. Reddy’s Laboratories Ltd announced that it has acquired the trademark rights of the breast cancer drug PRIMCYV® from Pfizer Products India Pvt Ltd for use in the Indian market.

  • Demand for Indian generic drugs explodes high in China

    The demand for Indian generic drugs has exploded high in China amid the massive COVID surge, with Chinese experts cautioning that fake versions of these drugs are flooding the market.

  • Inflammatory trigger a new clue in Alzheimer’s

    Scientists from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) reported that an inflammatory trigger like one present during viral infections is elevated in Alzheimer’s disease and progressive supranuclear palsy, a rare brain disorder.

    “We have identified a new trigger of brain inflammation in these disorders,” said Elizabeth Ochoa, PhD, study author from UT Health San Antonio. The finding, published in Science Advances, is novel for this reason, she said.

  • Lupin receives FDA nod for Fesoterodine Fumarate Extended-Release Tablets

    Global pharma major Lupin Limited announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, to market a generic equivalent of Toviaz® Extended-Release Tablets, 4 mg and 8 mg, of Pfizer Inc. The product will be manufactured at Lupin’s facility in Goa, India.

  • Protein complexes assemble at the cell membrane in a polarised manner

    Researchers at the Department of Microbiology and Cell Biology (MCB), Indian Institute of Science (IISc), Bengaluru, have deciphered how specific essential protein complexes are distributed across two different regions in the cell membrane. The findings also help us understand how they play a crucial role in coordinating chromosome segregation with cleavage furrow formation during anaphase. An article has been published on the IISc website, making this announcement.

  • How individual bacteria reacts when exposed to different antibiotics

    Bacterial perseverance is a new phenomenon that helps explain how bacteria adapt to survive antibiotic treatments. A group of researchers at Uppsala University have studied how individual bacteria react when exposed to different antibiotics. The result underlines the importance of adhering strictly to antibiotic prescriptions.

    Fighting bacterial diseases is a perpetual arms race between medical scientists developing new therapeutics and the pathogenic bacteria continuously changing their genetic makeup to survive the drugs.

  • Exercise restrains Insulin Production, breakthrough research

    When a fruit fly starts walking or flying, its insulin-producing cells are immediately inhibited. This could be one explanation for why exercise promotes health.

    Insulin is an essential hormone for humans and many other living creatures. Its best-known task is to regulate sugar metabolism. How it does this job is well understood. Much less is known about how the activity of insulin-producing cells and consequently the secretion of insulin is controlled.

  • Cipla & Ethris partner for the development of mRNA-based therapies

    Cipla Limited announced that its wholly-owned UK subsidiary, Cipla (EU) Limited has signed definitive agreements for equity investment of EUR 15 million in Ethris GmbH , a global leader in delivering mRNAs directly to the respiratory system including administration by inhalation.

  • Zydus gets USFDA node for insomnia drug

    Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) to market Triazolam Tablets USP, 0.125 mg and 0.25 mg.

    Triazolam tablets are used on a short-term basis to treat insomnia (difficulty falling asleep or staying asleep). It works by slowing activity in the brain to allow sleep. The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, India.

Subscribe to Pharma News